FAMDF
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.00 | $695,392 | -$3M |
| 2025 Q2 | -0.02 | $1M | -$3M |
| 2024 Q4 | 0.00 | $7M | $3M |
| 2024 Q2 | 0.00 | $7M | -$4M |
| 2023 Q4 | -0.02 | $1M | -$341,592 |
| 2023 Q2 | -0.01 | $2M | -$594,004 |
| 2022 Q4 | -0.01 | $0 | -$3M |
| 2022 Q2 | -0.01 | $0 | -$4M |